Telegraph.co.ukMerck immunotherapy fails to improve survival in head and neck cancerReuters(Reuters) – Merck & Co said on Monday that its Keytruda immunotherapy failed to extend survival in previously treated patients with advanced head and neck ca… Continue reading
Merck immunotherapy fails to improve survival in head and neck cancerWHTC(Reuters) – Merck & Co said on Monday that its Keytruda immunotherapy failed to extend survival in previously treated patients with advanced head and neck cancer more than the… Continue reading
Genome editing with CRISPR-Cas9 prevents angiogenesis of the retinaMedical XpressCRISPR-associated protein Cas9 (white) from Staphylococcus aureus based on Protein Database ID 5AXW. Credit: Thomas Splettstoesser (Wikipedia, CC BY-SA 4.0). A research te… Continue reading
HealthlineNew Gene Therapy Produces Hope for a New Era in Cancer …HealthlineGene-altering therapy on the cusp of FDA approval may soon be treating children with advanced leukemia.More CAR-T Therapies Sought | GenomeWebGenomeWeball 4 news articles&nbs… Continue reading
HealthlineNew Gene Therapy Produces Hope for a New Era in Cancer …HealthlineGene-altering therapy on the cusp of FDA approval may soon be treating children with advanced leukemia.More CAR-T Therapies Sought | GenomeWebGenomeWeball 4 news articles&nbs… Continue reading
Cellectis Granted Patent for CRISPR Use in T-CellsMarkets InsiderEP3004337 for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells. The patent will be issued on August 2, 2017. This therapeutic-f… Continue reading
Cellectis Granted Patent for CRISPR Use in T-CellsMarkets InsiderEP3004337 for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells. The patent will be issued on August 2, 2017. This therapeutic-f… Continue reading
Genetic Engineering & Biotechnology News (blog) |
Cellectis Granted T Cell CRISPR Patent in Europe
Genetic Engineering & Biotechnology News (blog) The bitter patent feud over CRISPR, a gene-editing tool with unprecedented potential, continues in the United States. Meanwhile, French biotech Cellectis is staking a claim to the technology in Europe. Cellectis announced that the European Patent … Cellectis Granted Patent for CRISPR Use in T-CellsBusiness Wire (press release) |